This four day program is ideal for those who are looking for an in-depth, hands-on introduction to Flow Cytometry. The instructors will focus on a broad spectrum of flow cytometric [….]
Flow Cytometry: Principles and Methods

This four day program is ideal for those who are looking for an in-depth, hands-on introduction to Flow Cytometry. The instructors will focus on a broad spectrum of flow cytometric [….]
This four day program is ideal for those who are looking for an in-depth, hands-on introduction to Flow Cytometry. Designed by active researchers, this workshop focuses on a broad spectrum [….]
Team taught by active researchers, this two day program is ideal for basic research and translational biology scientists who work with antibodies on a regular basis. This program which focuses [….]
This four day program is divided into a two-day symposium with lectures presented by world class scientists in the field of immuno-oncology and with representation by all the main multiplex [….]
This four day program is ideal for those who are looking for an in-depth, hands-on introduction to Flow Cytometry. Developed and taught by active researchers, this workshop will focus on [….]
This elementary course will uncover the fundamental pillars of Immunology, which include the cellular and molecular partners participating in the orchestration of an immune response. In addition, it will study [….]
This elementary course will uncover the fundamental pillars of Immunology, which include the cellular and molecular partners participating in the orchestration of an immune response. In addition, it will study [….]
Markus Weiss, who in this role is responsible for supporting the North American Business Units and Divisions has 18 years of experience in operationalizing strategy, preserving and growing value, scaling culture as well as business transformations. He is experienced in divisional, regional and country level leadership roles in technology, life science, manufacturing, construction and financial services.
Cerecor Rebrands to Avalo Therapeutics. Eighteen months after completing its merger with Aevi Genomic Medicine, Cerecor is rebranding to Avalo Therapeutics. The rebranding to Avalo reflects the company’s aims to focus on three core indications, on immunology, immuno-oncology, and rare genetic diseases.
Patented high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology.